Skip to main content
. 2016 Apr 1;12(4):e1005966. doi: 10.1371/journal.pgen.1005966

Fig 1. YRA1 overexpression and cell growth inhibition.

Fig 1

(A) Expression levels of the wild-type and the intron-less version of YRA1 placed under the control of tet and GAL1 promoters. Top, scheme showing the YRA1 intron-containing and intron-less constructs is shown. Middle, northern analysis of YRA1 mRNA in WT cells transformed with plasmids carrying tet::YRA1, tet::YRA1Δi, or the empty vector (-) (pCM184) grown in medium with 2% glucose and 5mg/ml doxycycline (tet OFF) and in medium with glucose and without doxycycline (tet ON) (upper panel). Bottom, northern analysis of YRA1 mRNA in WT cells transformed with plasmids carrying GAL::YRA1 and GAL::YRA1Δi constructs, or the corresponding empty vector (pRS413GAL) grown in medium with 2% glucose (GAL OFF) or in medium with 2% galactose (GAL ON) (lower panel). (B) Effect of YRA1 overexpression in mutants of DNA-damage checkpoint factors, recombination and DNA repair proteins and factors involved in DNA metabolism. Ten-fold serial dilutions of WT (BY4741 and W303-1A) and mutant strains transformed with plasmids carrying GAL::YRA1 and GAL::YRA1Δi constructs, and plated on minimal selective medium with either glucose (Glu) or galactose (Gal) are shown. Photographs were taken after 3 days of growth at 30°C.